Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 7, 2023
Reporting Period: Quarter ended September 30, 2023
Business Context: The filing serves as a notification of the company's financial results for the third quarter of 2023. The detailed results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the announcement of financial results but does not contain the specific numerical data within the body of this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific financial figures are located in Exhibit 99.1 (Press Release), which is not included in the input content.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2023, were announced.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the full text of the press release containing management commentary, guidance, and outlook is furnished as Exhibit 99.1.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover document. The filing includes a standard disclaimer that the information is furnished to comply with Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 7, 2023) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "Results of Operations" referenced in Item 2.02, as they are not present in the cover page.
- Check for any forward-looking statements or updated guidance included in the referenced press release.
- Confirm the company's status as an emerging growth company (indicated as checked in the filing) and its election regarding extended transition periods for accounting standards.